196 related articles for article (PubMed ID: 34927050)
1. Exclusive inhibition of IL-6 trans-signaling by soluble gp130
Berg AF; Ettich J; Weitz HT; Krusche M; Floss DM; Scheller J; Moll JM
Cytokine X; 2021 Dec; 3(4):100058. PubMed ID: 34927050
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
5. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
7. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
[TBL] [Abstract][Full Text] [Related]
8. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
9. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
[TBL] [Abstract][Full Text] [Related]
10. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
[TBL] [Abstract][Full Text] [Related]
11. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
12. Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S; Jenkins BJ; Garbers C; Moll JM; Scheller J
Nat Rev Immunol; 2023 Oct; 23(10):666-681. PubMed ID: 37069261
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis.
Sodenkamp J; Waetzig GH; Scheller J; Seegert D; Grötzinger J; Rose-John S; Ehlers S; Hölscher C
Immunobiology; 2012 Oct; 217(10):996-1004. PubMed ID: 22387074
[TBL] [Abstract][Full Text] [Related]
14. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
15. No inhibition of IL-27 signaling by soluble gp130.
Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
17. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
[TBL] [Abstract][Full Text] [Related]
18. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
19. A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling.
Lokau J; Garbers Y; Grötzinger J; Garbers C
iScience; 2021 Nov; 24(11):103309. PubMed ID: 34765926
[TBL] [Abstract][Full Text] [Related]
20. Exploratory assessment of the effect of systemic administration of soluble glycoprotein 130 on cognitive performance and chemokine levels in a mouse model of experimental traumatic brain injury.
Gober IG; Russell AL; Shick TJ; Vagni VA; Carlson JC; Kochanek PM; Wagner AK
J Neuroinflammation; 2024 Jun; 21(1):149. PubMed ID: 38840141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
